News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
******I LOVE IT!!!!!!!!******
You should repost this everytime shiznit slinger and his minions post the same garbage everyday🤣😂🤣😂🤣
Another day….
Another week….
Another big, fat, juicy, KBLB nothingburger….
with a side order of lies….
I do love the BSSlinger's, and multiple personalities, unhinged scramble over the years to constantly move the goalposts. They went from "not a real company", to "not possible for this company to make silkworms produce recombinant spider silk", to "not possible to scale up production", to "no company would want their product", to "no company would do business with them", to whether or not a company as huge as NIKE would have to disclose if they are doing business with KBLB for the spider silk they are producing.
Pretty soon they will be complaining that KBLB is only at $3 pps and not $10. Or KBLB is only producing 24 metric tonnes and not at the 25 they said they are capable of. Or the BO was only for $15 per share and not $20. It's fun to watch.
Bought some more today!!!
I hope everyone has an amazing weekend. Happy Father's Day to all!
KBLB is making what no others can.
Beyond Kong and Very Strong!
MCA
It’s the OTC; the bashturd’s playground. Right now they have the upper hand and good for them. Their reign is fast coming to an end. What the bashturd lowlifes fear the most is THHEEEE photo opportunity. The picture of the CEO, the COO, Dr. Kumar, all posing proudly with the company’s first ever commercial delivery to its’ first ever commercial customer. I would not be surprised in the least if the timing of this trip has taken that into account.
The company stubbed its’ toe when they first tried to commercialize. That ain’t gonna happen again. You can ridicule the CEO all you want but one thing he does not do is make the same mistake twice. He knows very well what is at stake. No stone has been left unturned. There is plenty of evidence to support legal action against the bashturds and their hideous sponsors but, let’s face it, he’s got bigger fish to fry.
The CEO has mentioned numerous times that moving to a better exchange has been in the cards for awhile. I think he has the ‘firepower’ to get us there whether the threshold is $2, $3, or $4. Whichever it is the CEO will figure it out. In the meantime a BO is certainly a possibility but for the time being I think that’s all it is. Right now, we need the breakthrough to commercialization via these three (3) contracted product delivery(s). This is crucial. This is crunch time. There is nobody in this world that is even close to our CEO when it comes to having a laser focus on this company and its’ upcoming commercialization.
That first announcement will be a huge ‘game-changer’ of a deal. Not in terms of dollar amount or kilos. The science, research & development, has always been impressive. The big question has always been, and continues to be, can you guys make this stuff in quantity? The answer to that question is looming on the horizon and getting closer each and every day. For the material science and textile industries it will be the equivalent to a 9.0+ mega-thrust earthquake. Buckle up, buttercup. Things are gonna change.
The clock is ticking (LOUDER than ever !!) … BUY MORE SHARES !!!
We are the * NEXT * BIG * THING *
Later, WBeacham
KBLB, "coming soon" since 2007....
LOL
Another day….
Another week….
Another big, fat, juicy, KBLB nothingburger….
with a side order of lies….
I hear the intent behind what you're saying—but let's not pretend that what we saw yesterday (and most days) is just retail traders chasing fib lines and volume bars.
KBLB's daily chart includes...
--Erratic high-low steps
--Multiple bid-whack stair-downs
--Minimal volume with exaggerated price movement
--End-of-day "control pin" to cap any recovery
That’s not “trader desperation.” That’s systemic suppression.
This isn’t startup volatility—it’s thinly veiled manipulation.
And downplaying it only helps the ones doing it.
Sure, customer names would be catalytic. But let’s not kid ourselves:
If Nike was announced, the same crowd suppressing this would still be out here dropping 500-share sells every 3 minutes just to frustrate momentum.
Because that’s the game—control perception, limit breakout, rinse sentiment.
And as for this:
“Sales in 2025 will be minimal…”
*******WRONG********
When a company becomes as large as Nike or any other International brand.....EVERY single company they do business with is small compared to them, lol. The size of the company is not the only metric said company uses when determining to do business. You are not giving ANY credence to KB or their recombinant spider silk. Get with the program! Be smart and welcome aboard!
I am going to have a party aboard my yacht that I bought with KB money and invite everyone on here, including you. Btw the name of the boat will be
<< does he, by law, have to release the NAMES of the customers??? >>
The answer is NO.
A large company would not want to have their name associated with an unknown penny stock that is just looking to gain fame and fortune by using a well-known brand name. They would have KBLB sign an NDA.
But the mental exercise is a waste of time, because no brand-name is going to be associated with this POS stock.
<< This SP goes through a battlefield of suppression daily! >>
The vast majority of "suppression" comes from the Scumbag CEO, due to his serial lying, and consistent dilution of shares.
Thanks, A-man for another sensational post! You are absolutely correct on all counts. GO KBLB! 
If you really want to know whether “things are on the up and up,” don’t just look at the first 3 minutes. Look at the 15 years of operational buildout finally reaching commercial scale.
Because when real sales hit? The chart won’t ask for permission. It’ll break the whole suppressive cycle. And I guarantee, it won’t be during the first candle. This SP goes through a battlefield of suppression daily! One doesn't have to be a chart guru to see the suppression, either. But the GREAT thing is, once we do achieve that "tipping point," this coiled SP will freaking take off and not look back. The suppression was important to the suppressors while the company developed. Those who suffered through it will be rewarded most, though! We're almost there!
Patrik.......Do you understand that the share price right now has been and is totally meaningless, UNLESS YOU ARE BUYING. It makes no difference whether or not the share price drops or not after anyone buys. It is inevitable in the stock market. Regardless, in the long run, this is all a waste of time worrying about the current state of the share price.
The OTC is like the wild west, no rules, no laws, where manipulation is the word of the day. There are two options coming, either an up list or a BO. I still favor the latter since it is less messy and does not involve having to dilute more shares. I hope and pray Kim chooses a BO, as long as we get at least eight eight dollars.
Remember, the price will move when it moves. In the meantime, these are golden opportunities to buy cheap shares. When the stock drops a lot, I buy. It is that simple. I mean Kim has told you what is coming. Not sure what the hell else you want. Quit being so negative and worrisome. Better days are imminent. Also, I expect to hear great news from Kim when they return from Vietnam. I am hoping they signed a deal with Cambodia. That would make my day! Good luck to you!
Thanks, SilkRoad! Yes, I am still a true believer after all these centuries. lol's. It amazes me about how so many investors just cannot see what is right in front of them and are selling rather than buying.They are sqandering a once in a life time opportunity to become rich IF they have enough shares. I have been backing up the truck for a very long time now. GO KBLB! 
Don’t fail to see what could be . . .
He cashmoney backing that truck up like a Kong. lol
I’m not eating them out of a can. No way. So I have a bold strategy …
https://www.amazon.com/ecoEat-Edible-Silkworm-Dehydrated-Insects/dp/B01N04D8AX/ref=asc_df_B01N04D8AX?mcid=38f8cd7319ee39b5b09be1a4e24630d9&hvocijid=12571398492679100542-B01N04D8AX-&hvexpln=73&tag=hyprod-20&linkCode=df0&hvadid=721245378154&hvpos=&hvnetw=g&hvrand=12571398492679100542&hvpone=&hvptwo=&hvqmt=&hvdev=m&hvdvcmdl=&hvlocint=&hvlocphy=9004660&hvtargid=pla-2281435178538&psc=1
Kong on. Someone is still a true believer after all these years! I hope it works out for you/us!
Spidersilk is coming soon!!!!!!!!!!
“Southeast Asia” suggests to me that they are going to Vietnam and Cambodia to make a deal(s). Better come back with my silk. We are here to make $$$.
Excellently stated, Eis. You are spot on regarding KBLB's share price in a BO situation. Many investors are so myopic that they cannot see their own noses thus causing them to sell shares of KBLB! I just keep buying their shares. GO KBLB!
****BREAKING NEWS*****MORE DILUTION****
The Scumbag CEO diluted almost 1 MILLION more shares.....
The O/S increased from 1,049,500,334 to 1,050,450,334. 📉
Almost 10 MILLION shares diluted so far this year.
Lots more dilution to come (over 200 MILLION more shares, according to SEC filings)....
Wash, rinse, repeat....
https://www.otcmarkets.com/stock/KBLB/security
<< from 247marketnews >>
Anyone that believes the BS pumping drivel that comes from 247marketnews shouldn't be investing in anything....
Not only does KBLB pay 247marketnews an exorbitant amount of money, but the Scumbag CEO probably writes that nonsense himself....
247MarketNews is a fake news organization that is paid by KBLB to provide pump pieces.
"247market news is being paid up to twenty-five thousand dollars a month for ongoing coverage of Kraig Labs"
"247 market news is being paid for editorials and investor traffic to the company news."
https://247marketnews.com/breaking-news-alert-kraig-labs-otcqb-kblb/
"Kraig Labs has maintained long-standing and productive working relationships with Hansel Capital and Karolus Maximus Kapital going back 11 or more years. These two firms provide the Company with support for shareholder inquiries and investor relations services. In December 2023, the Company signed an agreement with Karolus Maximus Kaptial for IR services. Under the terms of that agreement, they will receive 5,000,000 restricted shares and a monthly fee for services."
https://www.kraiglabs.com/safe-harbor-disclosure/
[Again, from 24/7marketnews - “Kraig is currently the only company in the world with a functional and scalable platform for spider silk mass production. This puts KBLB in a first-mover position in a sector projected to grow into a $42–$50 billion global market by the end of the decade.”]
Imagine having free reign as the only company producing the materials needed in a $42-$50 billion global market. A BO would be well over $10 per share. The long term outlook is much higher than that. Either way, KBLB pps is set to explode. No other competition in the near future.
Go KBLB!
Beyond Kong and Very Strong!
MCA
The KBLB investors who understand the company and what is happening recognize the tone and timber of this PR. It oozes CONFIDENCE. And senior management, as a collective, don’t travel hoping to shake a few hands, passing out prospectuses, etc. No, they are focussed and purpose-driven. Senior management goes on trips at the end of negotiations; to finalize and close the deals. Wanna bet Cambodia is on the itinerary?
“ … to reinforcing partnerships with current production collaborators, Kraig Labs leadership will evaluate options to onboard additional rearing capacity, including private partnerships and potential collaborations to further expand its manufacturing footprint.
From https://247marketnews.com/kraig-biocraft-advances-toward-first-ever-spider-silk-deliveries-to-luxury-and-performance-giants/ - “For decades, spider silk has been the holy grail of biomaterials—coveted for its unmatched strength, flexibility, and biocompatibility. Unlike DuPont’s (NYSE:DD) Kevlar, which relies on synthetic processes, spider silk offers a sustainable, biocompatible alternative that’s stronger than steel yet lighter than cotton. Kraig Labs has cracked the code, overcoming historical challenges to deliver mass-produced spider silk that’s ready to disrupt multiple sectors. While names remain undisclosed, imagine a brand like Nike."
(NYSE:NKE) leveraging spider silk’s sustainability and performance to bolster its image under incoming communications director Michael Gonda. This isn’t just a material—it’s a narrative of innovation and environmental responsibility that could redefine brand identities. Today’s letter is surely the type of advancements that Bolt’s (BSLK) top tier investment banks where hoping to accomplish when they sank hundreds of millions into the former unicorn.
Again, from 247marketnews - “Kraig is currently the only company in the world with a functional and scalable platform for spider silk mass production. This puts KBLB in a first-mover position in a sector projected to grow into a $42–$50 billion global market by the end of the decade.”
Why it matters: Spider silk is one of the strongest, lightest, and most versatile fibers on Earth—stronger than steel by weight (lighter than cotton), sustainable and biodegradable. Its applications range from performance apparel and composites to biomedical devices, aerospace, and national defense. As companies and governments alike look for advanced, eco-friendly materials, Kraig’s scalable platform gives it a competitive edge that could be nearly impossible to replicate in the near term.
|
Followers
|
659
|
Posters
|
|
|
Posts (Today)
|
2
|
Posts (Total)
|
287855
|
|
Created
|
05/04/08
|
Type
|
Free
|
| Moderators gimmegimmeminemine Money4Nothing-M4N WebSlinger | |||
Email: corporate@KraigLabs.com
KRAIG LABS WEBSITE FOR INVESTORS
Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR.
* Financial Statements * SEC Filings *
Outstanding Shares as of January 12, 2023
For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy.
Atlantic Highlands, New Jersey 07716
Phone: (732) 872-2727
(since August 14, 2013)
Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced.
Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers. Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider. These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins. With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market. The value for the chinese raw silk market alone is 3-5 billion per annum. With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins. The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions. Their second generation of transgenics are expected to be complete in 2011. These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from. These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum. The 3rd generation organisms are currently in the planning phase. These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.
Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming. The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd. The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider. Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed, including methods, organisms, and fibers produced.
MANAGEMENT
Kim Thompson, Founder and CEO
As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University.
He received his Juris Doctorate from the University of Michigan Law School in 1994.
Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications. As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.
Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.
Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.
Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.
With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.
Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.
Mr. Rice has over 13 years’ experience growing development stage businesses with a focus on technology development, commercialization, and go to market strategies. Mr. Rice holds a B.S. in Chemical engineering from Michigan Technological University.
Prior to joining Kraig Biocraft Laboratories Mr. Rice was the Director of Advanced Technologies for Ultra Electronics, AMI. In this role, Mr. Rice was responsible for the identification, capture, and execution of new technology programs. During his tenure with AMI, Rice secured more than twenty five million dollars in funded development programs from the US Department of Defense which his team successfully leveraged into commercially viable spinoff products. Mr. Rice was also responsible for technical sales, marketing, and promotion of AMI’s products and capabilities. Rice joined AMI as the third full time employee and helped to lead the organization through its rapid growth and ultimate acquisition by Ultra Electronics in 2011.
Earlier in his career Mr. Rice developed unique advanced manufacturing techniques, established and trained a production staff, led engineering development, authored numerous technical papers, and is a recognized subject matter expert. Mr. Rice holds 5 issued patents and numerous provisional patents.
Mr. Rice brings a history of transforming revolutionary ideas into viable commercial products.
Mr. Rice is currently completing his Masters of Business Administration through the Executive Program at the Eli Broad College of Business: Michigan State University.
Credit Randy StewartDespite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.
Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.
Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.
GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.
Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.
Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.
By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels
Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.
Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.
Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.
To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.
Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.
The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.
This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics
Credit Nir Nussbaum
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.
The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.
GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.
The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.
Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):
PHOTOS FROM VIETNAM POSTED JULY 6, 2018
ANN ARBOR, Mich., – January 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has successfully delivered the first two shipments of its highly specialized silkworms, which produce a silk with the physical characteristics of spider silk, to Vietnam.
Today’s announcement is the culmination of more than 5 years of work, and challenging negotiation, with the government of Vietnam. The silkworms from these first two shipments have already hatched and are now enjoying a fresh mulberry diet, so, for the first time in history, the global demand for spider silk materials has a viable, cost effective, and scalable solution.
“The dream of commercializing our powerful technology is now materializing. This marks a dramatic leap forward in Kraig Labs’ business plan for commercial production and mass marketing of cost effective recombinant spider silk, and becomes the foundation for an entirely new industry,” said, COO, Jon Rice. “To our long-term shareholders, who have taken this journey with us, as well as our team in the US and Vietnam, who have worked tirelessly to make this dream a reality, I cannot thank you enough. As we start the New Year, full of new opportunity, we truly have something incredible to celebrate.”
The Company has been working with leading sericulture experts, biotechnology institutions, and governmental agencies, in Vietnam, to further boost the silk industry with our revolutionary technology. Kraig Labs is currently finalizing renovation plans for a ~46,000 square foot production factory in Quang Nam Province, Vietnam.
“Our plan has always been to bring our technology to the silk producing regions of the world for rapid scale-up,” said, CEO and Founder, Kim Thompson. “Today we see the fruits of that effort. With its massive silk infrastructure and production capacity, Vietnam is an ideal location to launch our technology scale-up. Congratulations to our team and shareholders, as we prepare for the realization of large scale production.”
\
\
AI
